About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01576172

Abiraterone Acetate With or Without Veliparib in Treating Patients With Metastatic Prostate Cancer

Study identifier: NCT01576172
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Progressive metastatic hormone-resistant prostate cancer
  • On androgen-deprivation therapy
  • Willing to undergo biopsy of metastatic lesion or have adequate archival metastatic tissue which can be used for ETS fusion status
  • Patients can have up to 2 prior treatments
  • Patients with CNS metastasis are ineligible

Type of study:

Phase II

Treatment:
Patients will be randomized to two arms:

  • Patients in Arm 1 receive abiraterone acetate and prednisone on days 1-28
  • Patients in Arm 2 receive veliparib on days 1-28, as well as abiraterone acetate and prednisone beginning on day 8 of course 1 and day 1 of course 2 and all subsequent courses.

Study site:

Illinois
Chicago
University of Chicago
Contact: Walter M. Stadler 773-702-4150 wstadler@medicine.bsd.uchicago.edu

Evanston
Evanston CCOP-NorthShore University HealthSystem
Contact: Daniel H. Shevrin 847-570-2515 DShevrin@northshore.org

Indiana
Indianapolis
Indiana University Medical Center
Contact: Noah M. Hahn 317-948-1186 nhahn@iupui.edu

Maryland
Baltimore
Johns Hopkins University
Contact: Emmanuel S. Antonarakis 410-502-7528 eantona1@jhmi.edu

Michigan
Ann Arbor
University of Michigan University Hospital
Contact: Maha H. Hussain 734-936-8906 mahahuss@umich.edu

North Carolina
Chapel Hill
University of North Carolina Recruiting
Contact: Young E. Whang 919-843-9983 ywhang@med.unc.edu

 

Page updated 06/10/13


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org